We argue this difference is not likely to be due to potential confounds such as differences in the number of pre- and post-cTBS MEPs, BDNF Val66Met SNP, ADHD comorbidity, or neuroactive medications between the two groups. This evidence concerns the gene BDNF and attention deficit-hyperactivity disorder.